ESR1 and breast carcinoma: AR-targeting has been introduced recently as a novel therapeutic option in TNBC [22], and a phase II trial of Bicatulamide (Casodex, AstraZeneca; nonsteroidal anti-androgen) treatment is ongoing in women with advanced AR+/ER−/PR− breast cancer.